Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BMP10 propeptides and related methods
    Patent number: 8772234
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: July 8, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf
  • GDF3 propeptides and related methods
    Patent number: 8765670
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 1, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Compositions and methods for increasing serum half-life
    Patent number: 8722615
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: May 13, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar
  • Methods for increasing thermogenic adipocytes
    Patent number: 8703694
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: April 22, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS
    Publication number: 20140079700
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 20, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: John Knopf, Jasbir Seehra
  • Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
    Patent number: 8642031
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: February 4, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Methods of promoting fat loss comprising administering an ALK7 inhibitor
    Patent number: 8637450
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Method for promoting bone growth using activin-actriia antagonists
    Patent number: 8629109
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: January 14, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF
    Publication number: 20130344067
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
  • METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTRIIA ANTIBODY
    Publication number: 20130295089
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 7, 2013
    Inventors: John Knopf, Jasbir Seehra
  • METHODS AND COMPOSITIONS FOR INCREASING RED BLOOD CELLS
    Publication number: 20130281371
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • Method of promoting bone growth by an anti-activin A antibody
    Patent number: 8486403
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: July 16, 2013
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK1 receptor and ligand antagonist and uses thereof
    Patent number: 8455428
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: June 4, 2013
    Assignee: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
  • COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE
    Publication number: 20130084291
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Application
    Filed: June 8, 2012
    Publication date: April 4, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar, Erik Vogan
  • ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS
    Publication number: 20130065299
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 14, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20130039910
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: April 13, 2012
    Publication date: February 14, 2013
    Applicant: ACCELERON PHARMA, INC.
    Inventors: ASYA GRINBERG, JOHN KNOPF, RAVINDRA KUMAR, ROBERT S. PEARSALL, JASBIR SEEHRA, KRISTIAN PIETRAS
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20130040896
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: April 13, 2012
    Publication date: February 14, 2013
    Applicant: ACCELERON PHARMA, INC.
    Inventors: ASYA GRINBERG, JOHN KNOPF, RAVINDRA KUMAR, ROBERT S. PEARSALL, JASBIR SEEHRA, KRISTIAN PIETRAS
  • Activin-actriia antagonists for inhibiting germ cell maturation
    Patent number: 8367611
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: February 5, 2013
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • CERBERUS/COCO DERIVATIVES AND USES THEREOF
    Publication number: 20130029908
    Abstract: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.
    Type: Application
    Filed: June 26, 2012
    Publication date: January 31, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA
    Publication number: 20130004489
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Application
    Filed: April 30, 2012
    Publication date: January 3, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar